Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 07 04:00PM ET
0.9607
Dollar change
-0.0194
Percentage change
-1.98
%
Index- P/E- EPS (ttm)-1.24 Insider Own3.02% Shs Outstand90.08M Perf Week-1.47%
Market Cap86.54M Forward P/E- EPS next Y-0.77 Insider Trans3.32% Shs Float87.36M Perf Month-14.22%
Income-96.90M PEG- EPS next Q-0.23 Inst Own62.04% Short Float4.03% Perf Quarter-19.27%
Sales0.00M P/S- EPS this Y54.58% Inst Trans5.76% Short Ratio3.69 Perf Half Y-17.89%
Book/sh0.46 P/B2.10 EPS next Y20.17% ROA-147.12% Short Interest3.52M Perf Year-22.52%
Cash/sh0.66 P/C1.47 EPS next 5Y32.90% ROE-216.24% 52W Range0.92 - 2.11 Perf YTD-3.93%
Dividend Est.- P/FCF- EPS past 5Y31.12% ROI-234.04% 52W High-54.47% Beta1.95
Dividend TTM- Quick Ratio2.71 Sales past 5Y0.00% Gross Margin- 52W Low4.08% ATR (14)0.07
Dividend Ex-Date- Current Ratio2.71 EPS Y/Y TTM61.97% Oper. Margin- RSI (14)41.90 Volatility4.98% 6.80%
Employees77 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price13.17
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q52.90% Payout- Rel Volume0.44 Prev Close0.98
Sales Surprise-100.00% EPS Surprise-9.89% Sales Q/Q- EarningsNov 07 BMO Avg Volume955.70K Price0.96
SMA20-3.07% SMA50-10.98% SMA200-24.54% Trades Volume424,307 Change-1.98%
Date Action Analyst Rating Change Price Target Change
Nov-25-24Initiated H.C. Wainwright Buy $10
Sep-09-24Resumed Leerink Partners Outperform $5
Aug-27-24Initiated B. Riley Securities Buy $6
Oct-21-22Downgrade SVB Leerink Outperform → Mkt Perform $5
Sep-19-22Resumed H.C. Wainwright Buy $26
Apr-15-21Initiated Aegis Capital Buy $55
Mar-24-21Initiated JMP Securities Mkt Outperform $55
Oct-02-20Initiated SVB Leerink Outperform $45
Aug-26-20Initiated Piper Sandler Overweight $71
Aug-07-20Resumed ROTH Capital Buy $64
Feb-04-25 06:30AM
Jan-07-25 06:30AM
Dec-03-24 03:45PM
Nov-26-24 06:30AM
Nov-14-24 06:35AM
06:30AM Loading…
Nov-13-24 06:30AM
Nov-09-24 08:00AM
Nov-07-24 06:41AM
06:30AM
Oct-31-24 06:30AM
Oct-29-24 06:30AM
Oct-22-24 06:30AM
Oct-09-24 05:31PM
Sep-18-24 06:30AM
Sep-04-24 06:30AM
06:30AM Loading…
Aug-28-24 06:30AM
Aug-08-24 06:34AM
06:30AM
Aug-01-24 06:30AM
Jul-24-24 06:30AM
Jul-09-24 06:30AM
May-30-24 07:03AM
May-28-24 06:30AM
May-23-24 06:00AM
May-20-24 10:00AM
May-17-24 02:35PM
May-16-24 05:54PM
May-09-24 10:23AM
06:58AM
May-08-24 06:36AM
06:30AM Loading…
06:30AM
May-06-24 06:30AM
May-01-24 10:02AM
06:30AM
Apr-30-24 06:30AM
Apr-29-24 11:11AM
Apr-04-24 06:30AM
Mar-21-24 12:14PM
11:37AM
Mar-20-24 06:30AM
Mar-08-24 06:53AM
Mar-07-24 06:30AM
Feb-29-24 06:30AM
Feb-23-24 09:02PM
11:04AM
Feb-22-24 10:59AM
06:30AM
Feb-15-24 06:30AM
Feb-01-24 06:30AM
Jan-05-24 06:35AM
06:30AM
Nov-21-23 06:30AM
Nov-14-23 01:25PM
06:36AM
06:30AM
Nov-07-23 06:30AM
Nov-02-23 06:30AM
Oct-26-23 06:30AM
Oct-24-23 07:51AM
Oct-16-23 06:30AM
Oct-15-23 06:30AM
Oct-11-23 06:30AM
05:15AM
Oct-10-23 09:07AM
Oct-09-23 04:01PM
Oct-04-23 06:30AM
Sep-06-23 06:30AM
Aug-21-23 08:00AM
Aug-17-23 06:30AM
Aug-07-23 09:50AM
Aug-03-23 06:47AM
06:30AM
Aug-01-23 06:30AM
Jul-28-23 04:19PM
Jul-27-23 06:30AM
Jul-25-23 08:00AM
Jul-24-23 10:33AM
Jun-29-23 06:30AM
Jun-27-23 09:56AM
09:11AM
Jun-26-23 03:44PM
May-31-23 07:42AM
May-30-23 06:30AM
May-17-23 10:00AM
06:30AM
May-16-23 01:07PM
May-11-23 06:40AM
06:30AM
May-09-23 06:30AM
May-06-23 06:30AM
May-04-23 06:30AM
Apr-27-23 06:30AM
Apr-26-23 06:30AM
Apr-13-23 08:00AM
Apr-06-23 02:10PM
Apr-05-23 12:30PM
06:30AM
Mar-02-23 06:30AM
Feb-28-23 05:22AM
Feb-26-23 08:23AM
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rudick Richard AlanDirectorNov 12 '24Buy1.1587,300100,36987,300Nov 13 02:13 PM